Who is the CEO of Evotec SE?

Dr. Mario Polywka DPHIL, Ph.D. is a business executive who currently serves as the CEO of Evotec SE.

What is the Revenue Growth of Evotec SE?

Revenue growth data for Evotec SE is currently unavailable.

What is Evotec SE operating Margin?

Evotec SE operating margin is -19.04% which shows how much profit EVT.SW earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Evotec SE operate?

Evotec SE falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Evotec SE revenue growth?

Revenue growth data for Evotec SE is currently unavailable.

Evotec SE

EVT.SW•SIX

HealthcareDrug Manufacturers - Specialty & Generic

$26.96

$0.00(0.00%)

Evotec SE (EVT.SW) Stock Overview

Explore Evotec SE’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for EVT.SWStats details for EVT.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for EVT.SWAnalyst Recommendations details for EVT.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

CEO

Dr. Mario Polywka DPHIL, Ph.D.

Employees

5,055

Headquarters

Essener Bogen 7, Hamburg

Founded

2014